ReviewCancers2025
Sexual Function After Laser Therapy for Penile Cancer: A Systematic Review.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPenile cancer is rare but rising in incidence. Any optimal treatment must balance oncologic control with preservation of sexual and urinary function.
objectivesTo evaluate sexual function, patient satisfaction, and oncologic outcomes after carbon dioxide (CO
methodsA systematic review was conducted in accordance with PRISMA 2020. We searched PubMed, Embase, Scopus, Google Scholar, ScienceDirect, ClinicalTrials.gov, and conference proceedings from January 2000 to 5 February 2025 for observational studies reporting sexual function after laser therapy. Risk of bias was assessed with the Newcastle-Ottawa Scale (NOS) and certainty of evidence with Grading of Recommendations Assessment, Development, and Evaluation (GRADE).
resultsEleven studies comprising 593 patients were included, mostly carcinoma in situ or T1. Local recurrence occurred in 6-19% of patients with Tis/T1 and 17-42% in ≥T2. Across laser types, 59-72% of patients retained erectile function, 50-100% reported sexual satisfaction, and 80-100% reported satisfaction with the cosmetic outcomes, with some degree of variation. Reports on libido and orgasm were heterogeneous and generally unvalidated. General patient satisfaction was high but often assessed using non-validated instruments.
conclusionsLaser therapy is a reasonable penile-sparing option for Tis/T1 disease, but mandates strict surveillance. Data are insufficient to support its use for ≥T2 tumors. Laser therapy generally preserves sexual function, but heterogeneous and non-standardized reporting limits firm conclusions. Prospective studies with standardized patient-reported outcome measures are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.